Neuromuscular Transmission and Its Pharmacological Blockade. Part 2: Pharmacology of Neuromuscular Blocking Agents

Overview

Journal Pharm World Sci

Publisher Springer

Specialties Pharmacology
Pharmacy

Date 1997 Feb 1

PMID 9089750

Authors

L H Booij

Affiliations

Soon will be listed here.

Abstract

Clinically, neuromuscular blockade is induced with either depolarizing or non-depolarizing relaxants. Suxamethonium is the only depolarizing relaxant still in use. It is hydrolysed in the plasma by pseudo-cholinesterase (plasma cholinesterase). In some patients and in particular diseases the plasma cholinesterase activity is low and hence the effect of suxamethonium prolonged. Suxamethonium is characterized by side-effects such as myalgia, fasciculations and increase in intraocular, intracranial and intragastric pressure. More serious adverse reactions are masseter muscle spasm and potassium release, in patients with some neuromuscular diseases and increase in extrajunctional acetylcholine receptors. As non-depolarizing muscle relaxants benzylisoquinolines and steroidal compounds are mainly used. Each relaxant has its own pharmacological characteristics. The effect of most relaxants depends on liver and renal function because the pharmacokinetic behaviour is strongly dependent on these organs. Also, acid base balance disturbances, change in temperature, and neurological diseases have an effect on the profile of the relaxants. A number of drugs (anaesthetics, antibiotics, antiepileptics, etc.) have an effect on neuromuscular transmission, and thus interact with the relaxants. Some non-depolarizing relaxants cause histamine release and cardiovascular effects.

References

Smith C, Donati F, Bevan D . Effects of succinylcholine at the masseter and adductor pollicis muscles in adults. Anesth Analg. 1989; 69(2):158-62. View

Ramanathan J, Sibai B, Pillai R, Angel J . Neuromuscular transmission studies in preeclamptic women receiving magnesium sulfate. Am J Obstet Gynecol. 1988; 158(1):40-6. DOI: 10.1016/0002-9378(88)90772-7. View

Gage P, Hamill O . Effects of anesthetics on ion channels in synapses. Int Rev Physiol. 1981; 25:1-45. View

Sokoll M, Gergis S . Antibiotics and neuromuscular function. Anesthesiology. 1981; 55(2):148-59. DOI: 10.1097/00000542-198108000-00011. View

Cason B, Baker D, Hickey R, Miller R, Agoston S . Cardiovascular and neuromuscular effects of three steroidal neuromuscular blocking drugs in dogs (ORG 9616, ORG 9426, ORG 9991). Anesth Analg. 1990; 70(4):382-8. DOI: 10.1213/00000539-199004000-00007. View

Singh Y, Marshall I, Harvey A . Pre- and postjunctional blocking effects of aminoglycoside, polymyxin, tetracycline and lincosamide antibiotics. Br J Anaesth. 1982; 54(12):1295-306. DOI: 10.1093/bja/54.12.1295. View

Nigrovic V, Banoub M . Pharmacokinetic modelling of a parent drug and its metabolite. Atracurium and laudanosine. Clin Pharmacokinet. 1992; 22(5):396-408. DOI: 10.2165/00003088-199222050-00006. View

SARNER J, Brandom B, Cook D, Dong M, Horn M, Woelfel S . Clinical pharmacology of doxacurium chloride (BW A938U) in children. Anesth Analg. 1988; 67(4):303-6. View

Erkola O . Effects of precurarisation on suxamethonium-induced postoperative myalgia during the first trimester of pregnancy. Acta Anaesthesiol Scand. 1990; 34(1):63-7. DOI: 10.1111/j.1399-6576.1990.tb03043.x. View

10.

Miller R, Matteo R, Benet L, Sohn Y . The pharmacokinetics of d-tubocurarine in man with and without renal failure. J Pharmacol Exp Ther. 1977; 202(1):1-7. View

11.

Hughes R, Chapple D . The pharmacology of atracurium: a new competitive neuromuscular blocking agent. Br J Anaesth. 1981; 53(1):31-44. DOI: 10.1093/bja/53.1.31. View

12.

Rosenberg H, Gronert G . Intractable cardiac arrest in children given succinylcholine. Anesthesiology. 1992; 77(5):1054. DOI: 10.1097/00000542-199211000-00040. View

13.

Pedersen T, Eliasen K, Henriksen E . A prospective study of risk factors and cardiopulmonary complications associated with anaesthesia and surgery: risk indicators of cardiopulmonary morbidity. Acta Anaesthesiol Scand. 1990; 34(2):144-55. DOI: 10.1111/j.1399-6576.1990.tb03059.x. View

14.

Savarese J, Ginsburg S, Lee S, KITZ R . The pharmacology of new short-acting nondepolarizing ester neuromuscular blocking agents: clinical implications. Anesth Analg. 1973; 52(6):982-8. View

15.

Levy J, Davis G, Duggan J, Szlam F . Determination of the hemodynamics and histamine release of rocuronium (Org 9426) when administered in increased doses under N2O/O2-sufentanil anesthesia. Anesth Analg. 1994; 78(2):318-21. DOI: 10.1213/00000539-199402000-00020. View

16.

SHANKS C, Fragen R, Pemberton D, Katz J, Risner M . Mivacurium-induced neuromuscular blockade following single bolus doses and with continuous infusion during either balanced or enflurane anesthesia. Anesthesiology. 1989; 71(3):362-6. DOI: 10.1097/00000542-198909000-00008. View

17.

van den Broek L, Wierda J, Proost J, Hommes F, Agoston S . Clinical pharmacology of ORG 7617, a short-acting non-depolarizing neuromuscular blocking agent. Eur J Clin Pharmacol. 1994; 46(3):225-9. DOI: 10.1007/BF00192553. View

18.

van der Spek A, Reynolds P, Fang W, Ashton-Miller J, Stohler C, Schork M . Changes in resistance to mouth opening induced by depolarizing and non-depolarizing neuromuscular relaxants. Br J Anaesth. 1990; 64(1):21-7. DOI: 10.1093/bja/64.1.21. View

19.

Doll D, Rosenberg H . Antagonism of neuromuscular blockage by theophylline. Anesth Analg. 1979; 58(2):139-40. View

20.

Wali F . Interactions of nifedipine and diltiazem with muscle relaxants and reversal of neuromuscular blockade with edrophonium and neostigmine. J Pharmacol. 1986; 17(3):244-53. View